| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 722 | 494 | 1,025 | 376 |
| Cost of revenues | 533 | 529 | 656 | 243 |
| Gross profit | 189 | -35 | 369 | 133 |
| Research and development | 221 | 972 | 530 | 249 |
| Selling and marketing | 812 | 717 | 349 | 181 |
| General and administrative | 1,403 | 2,252 | 1,342 | 673 |
| Total operating expenses | 2,436 | 3,941 | 2,221 | 1,103 |
| Loss from operations | -2,247 | -3,976 | -1,852 | -970 |
| Interest expense | - | 144 | 53 | 33 |
| Warrant modification expense | - | - | 623 | - |
| Interest expense | 53 | - | - | - |
| Financial income, net | 2,845 | 211 | -10 | 8 |
| Change in fair value of convertible note | - | - | 58 | - |
| Income (loss) before taxes on income | 545 | -3,909 | -2,480 | -995 |
| Income tax expenses | 35 | 62 | 15 | 3 |
| Net income (loss) | 510 | -3,971 | -2,495 | -998 |
| Deemed contribution | - | -3,815 | - | - |
| 8 dividend on convertible preferred series x | 758 | 344 | - | - |
| 9 dividend on convertible preferred series h | 223 | - | - | - |
| Deemed dividend for down round on series h | 399 | - | - | - |
| Deemed contribution on repurchase of preferred series x | -90 | - | - | - |
| Net loss available to common stockholders | -780 | -500 | - | - |
| Basic net loss available for holders of common stock | -0.91 | -1.03 | - | -0.36 |
| Diluted net loss available for holders of common stock | -0.91 | -1.03 | 3.98 | -0.36 |
| Weighted average common stock outstanding, basic | 858,434 | 484,566 | 626,150 | 2,803,181 |
| Weighted average common stock outstanding, diluted | 858,434 | 484,566 | 626,150 | 2,803,181 |
NanoVibronix, Inc. (NAOV)
NanoVibronix, Inc. (NAOV)